OptimizeRx Corp — Director's Dealing 2022

Jan 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2021-12-30

Reporting Person: Vos Ellen O'Connor (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-30	Restricted Stock Units	$	A	409	Acquired		Common Stock (409)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on December 30, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction.

F3: Not applicable.